148573 Use of electronic health records to promote regular screening for hepatocellular carcinoma in persons with chronic hepatitis B or hepatitis C infection

Sunday, November 4, 2007

Manon K. England, BS , Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK
Henry H. Cagle, BS , Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK
Mary M. Snowball, RN , Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK
Lisa J. Townshend, MSN, FNP , Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK
Susan E. Negus, RN , Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK
James L. Williams, BSN, ANP , Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK
Brian J. McMahon, MD , Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK
Background: Hepatitis B (HBV) and hepatitis C virus (HCV) are infectious agents that place persons at-risk for hepatocellular carcinoma (HCC). Studies show that elevated alpha-fetoprotein (AFP) and alanine aminotransferase (ALT) in sera are associated with the occurrence and progression of HCC. In patients at-risk, electronic health records (EHR) can be used to promote regular serologic screening and facilitate early, at a potentially resectable stage, HCC detection. Methods: The Liver Disease and Hepatitis Program established an EHR-based HCV/HBV registry to improve patient tracking/management. Patients are Alaska Native or American Indian people who are members of a statewide integrated healthcare system. Biannually, patients are mailed a letter encouraging them to have a blood draw. Follow-up letters notify patients of their results or if additional testing is needed. Results: In 2006, 2,298 patients were on the HBV/HCV registry: 1,758 letters were sent to patients with a mailing address and 1,173 patients had Ан1 blood draw. Liver imaging was recommended for 55 patients with elevated AFP (Ан15 ng/ml) and 523 patients with elevated ALT (Ан40 ng/ml) were evaluated for antiviral treatment; 3 patients were diagnosed with HCC. Conclusions: Among HBV/HCV carriers, the use of EHR can serve to promote regular screening for HCC and potentially prevent negative clinical outcomes. As more US primary care practices covert to an EHR system, such systems could be used to target and screen Asian and other populations with a high incidence of HBV carriers and be useful in the monitoring of persons with diabetes and other chronic diseases.

Learning Objectives:
1) Define how electronic health records are used to manage clinical data and promote disease indicator screening. 2) Describe how an application for electronic health records is used in patients with chronic hepatitis B or hepatitis C infection. 3) Evaluate the efficacy of using electronic health records in the management of patients at risk for hepatocellular carcinoma.

Keywords: Chronic Diseases, Data/Surveillance

Presenting author's disclosure statement:

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.